Key result
Carvedilol reduces myocardial HNE-modified protein levels by ~40% in dilated cardiomyopathy, alongside improved cardiac function.
Why the study?
Direct evidence of oxidative stress generation in human failing myocardium and the effect of carvedilol on oxidative stress in these hearts had not been assessed.
Does carvedilol reduce myocardial oxidative stress in patients with dilated cardiomyopathy?
Population
23 patients with dilated cardiomyopathy and 13 control subjects with normal cardiac function
Comparison
Myocardial oxidative stress levels before and after carvedilol treatment versus controls
Design
Immunohistochemical cohort study with pre- and post-treatment analysis
Follow-up
Mean 9±4 months
Authors
Loading...
Carvedilol was associated with reduced myocardial oxidative stress in dilated cardiomyopathy; hypothesis-generating and should not yet change practice.
Does carvedilol reduce myocardial oxidative stress in patients with dilated cardiomyopathy?
Effect estimate: 40% decrease
p-value: p=<0.005
Carvedilol reduces elevated myocardial oxidative stress in patients with dilated cardiomyopathy, providing mechanistic insight into its benefits in heart failure.
Nakamura et al. (2002) studied Dilated cardiomyopathy (n=36). Carvedilol vs. Baseline (before treatment) was evaluated on Myocardial HNE-modified protein levels (40% decrease, p=<0.005). Carvedilol administration decreased myocardial HNE-modified protein levels by 40% (P<0.005) in patients with dilated cardiomyopathy, alongside amelioration of cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: